AFT Announces FDA Issues Tentative Approval For ScomaraAFT Pharmaceuticals (NZX: AFT; ASX: AFP), today announces that the US Food and Drug Administration (FDA) has issued a tentative approval for Scomara (rapamycin 0.5% cream) for treatment of Facial Angiofibromas in Tuberous Sclerosis (FA in TSC). However, the orphan exclusivity granted in the US does not apply in many other significant markets around the world, where FDA approval will support regulatory approval. These markets include Canada, Australia, New Zealand, where AFT operates directly itself, and many markets in Asia. In these markets AFT believes Scomara will have a competitive advantage over the existing orphan product because the medicine is only applied once a day and it is stored at ambient temperature. However, the tentative approval is a catalyst for AFT to develop new and significant markets for the medicine outside the US which is positive.”